Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease | Zendy

Olivia Simmons | Zendy; Phillip B. Maples | Zendy; Neil Senzer | Zendy; John Nemunaitis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease

Author(s) -

Olivia Simmons,

Phillip B. Maples,

Neil Senzer,

John Nemunaitis

Publication year - 2012

Publication title -

isrn oncology

Language(s) - English

Resource type - Journals

eISSN - 2090-567X

pISSN - 2090-5661

DOI - 10.5402/2012/247657

Subject(s) - rna interference , small hairpin rna , sarcoma , gene silencing , cancer research , ewing's sarcoma , medicine , biology , gene , bioinformatics , rna , computational biology , genetics , pathology

Ewing's sarcoma tumors are associated with chromosomal translocation between the EWS gene and the ETS transcription factor gene. These unique target sequences provide opportunity for RNA interference(i)-based therapy. A summary of RNAi mechanism and therapeutically designed products including siRNA, shRNA and bi-shRNA are described. Comparison is made between each of these approaches. Systemic RNAi-based therapy, however, requires protected delivery to the Ewing's sarcoma tumor site for activity. Delivery systems which have been most effective in preclinical and clinical testing are reviewed, followed by preclinical assessment of various silencing strategies with demonstration of effectiveness to EWS/FLI-1 target sequences. It is concluded that RNAi-based therapeutics may have testable and achievable activity in management of Ewing's sarcoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research